CORRECTION

Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care - Seite 3

The HCP survey was conducted online by The Harris Poll on behalf of Arcutis Biotherapeutics among 601 HCPs (including dermatologists, NPs, and PAs) specializing in dermatology who see at least 1 patient per week and regularly see 1+ patients with seborrheic dermatitis per year. The survey was conducted December 16, 2021 through January 19, 2022. For Dermatologists, figures for years in practice, gender, and region were weighted where necessary to bring the data into line with actual proportions in the population. For NP/PAs, raw data were not weighted and are therefore only representative of the individuals who completed the survey.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses its unique dermatology development platform coupled with its dermatology expertise to build differentiated therapies against biologically validated targets. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
[e-mail]

Investors
Eric McIntyre, Head of Investor Relations
[e-mail]

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1d6f64a9-de26-481b ...

https://www.globenewswire.com/NewsRoom/AttachmentNg/dce5a7ad-1702-4227 ...